An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.
Akila Samiiya, Lead Analyst at Beroe and Rahul R Patil, Medzus, break down what the rise of generics means for drug delivery device procurement and what leaders should be doing about it now.
Related Reading
31 Jul, 2026
Conflicts escalate, jet fuel takes a hit. U.S. analysts are confident - for now